MX2023013815A - Antagonista del ligando del cumulo de diferenciacion 40 (cd40l) y usos del mismo en el tratamiento de la nefritis lupica. - Google Patents
Antagonista del ligando del cumulo de diferenciacion 40 (cd40l) y usos del mismo en el tratamiento de la nefritis lupica.Info
- Publication number
- MX2023013815A MX2023013815A MX2023013815A MX2023013815A MX2023013815A MX 2023013815 A MX2023013815 A MX 2023013815A MX 2023013815 A MX2023013815 A MX 2023013815A MX 2023013815 A MX2023013815 A MX 2023013815A MX 2023013815 A MX2023013815 A MX 2023013815A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- lupus nephritis
- cd40l antagonist
- cd40l
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191514P | 2021-05-21 | 2021-05-21 | |
| US202163235520P | 2021-08-20 | 2021-08-20 | |
| PCT/US2022/030290 WO2022246225A1 (en) | 2021-05-21 | 2022-05-20 | Cd40l antagonist and uses thereof in the treatment of lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013815A true MX2023013815A (es) | 2024-01-09 |
Family
ID=82100122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013815A MX2023013815A (es) | 2021-05-21 | 2022-05-20 | Antagonista del ligando del cumulo de diferenciacion 40 (cd40l) y usos del mismo en el tratamiento de la nefritis lupica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240084024A1 (https=) |
| EP (1) | EP4340867A1 (https=) |
| JP (1) | JP2024519904A (https=) |
| KR (1) | KR20240012473A (https=) |
| AU (1) | AU2022276507A1 (https=) |
| BR (1) | BR112023024153A2 (https=) |
| CA (1) | CA3219742A1 (https=) |
| IL (1) | IL308488A (https=) |
| MX (1) | MX2023013815A (https=) |
| WO (1) | WO2022246225A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024152001A1 (en) * | 2023-01-13 | 2024-07-18 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome |
| KR20250162587A (ko) * | 2023-03-28 | 2025-11-18 | 비엘라 바이오, 인크. | 쇼그렌 증후군의 치료 및 예방을 위한 cd40l 특이적 tn3 유래 스캐폴드 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753567A1 (en) * | 2011-10-11 | 2020-12-23 | Viela Bio, Inc. | Cd40l-specific tn3-derived scaffolds and methods of use thereof |
| KR20260016618A (ko) * | 2018-09-26 | 2026-02-03 | 비엘라 바이오, 인크. | Cd40l 길항제 및 이의 용도 |
-
2022
- 2022-05-20 AU AU2022276507A patent/AU2022276507A1/en active Pending
- 2022-05-20 JP JP2023571882A patent/JP2024519904A/ja active Pending
- 2022-05-20 BR BR112023024153A patent/BR112023024153A2/pt unknown
- 2022-05-20 MX MX2023013815A patent/MX2023013815A/es unknown
- 2022-05-20 EP EP22731386.3A patent/EP4340867A1/en active Pending
- 2022-05-20 IL IL308488A patent/IL308488A/en unknown
- 2022-05-20 WO PCT/US2022/030290 patent/WO2022246225A1/en not_active Ceased
- 2022-05-20 CA CA3219742A patent/CA3219742A1/en active Pending
- 2022-05-20 KR KR1020237043917A patent/KR20240012473A/ko active Pending
-
2023
- 2023-11-15 US US18/509,836 patent/US20240084024A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022246225A1 (en) | 2022-11-24 |
| CA3219742A1 (en) | 2022-11-24 |
| EP4340867A1 (en) | 2024-03-27 |
| IL308488A (en) | 2024-01-01 |
| US20240084024A1 (en) | 2024-03-14 |
| JP2024519904A (ja) | 2024-05-21 |
| BR112023024153A2 (pt) | 2024-02-06 |
| AU2022276507A9 (en) | 2023-12-14 |
| AU2022276507A1 (en) | 2023-12-07 |
| KR20240012473A (ko) | 2024-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020000690A (es) | Compuestos heterociclicos como antagonistas de adenosina. | |
| PH12021551290A1 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021008650A (es) | Compuestos heterociclicos como antagonistas de adenosina. | |
| PH12021551689A1 (en) | Cgrp antagonists for treating migraine breakthrough | |
| MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
| MX2021003514A (es) | Antagonista del ligando del grupo de diferenciacion 40 (cd40l) y usos del mismo. | |
| MX2023013815A (es) | Antagonista del ligando del cumulo de diferenciacion 40 (cd40l) y usos del mismo en el tratamiento de la nefritis lupica. | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| MX2021004598A (es) | Inhibidores selectivos de rgmc y el uso de los mismos. | |
| PH12023552741A1 (en) | Psilocybin Compositions, Methods Of Making And Methods Of Using The Same | |
| MX2020000693A (es) | Compuestos de 1,8-naftiridinona, y usos de los mismos. | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| PH12020551820A1 (en) | Methods of treating cancer | |
| MX2025005240A (es) | Métodos para el tratamiento de la nefritis lúpica mediante el uso de antagonistas de fcrn | |
| JOP20220168A1 (ar) | طرق علاج الطحال | |
| MX2021010989A (es) | Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica. | |
| MX2026002367A (es) | Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso | |
| MX2019015280A (es) | Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias. | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| EP3768702A4 (en) | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) THERAPY FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | |
| MX2022004121A (es) | Derivados de homopiperazinil y homopiperidinil quinazolin-4(3h)-ona que tienen actividad multimodal contra el dolor. | |
| MX2022007516A (es) | Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos. | |
| MX2024003985A (es) | Andamios derivados de tn3 especificos para cd40l para su uso en el tratamiento y prevencion de la artritis reumatoide. |